Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Blends · Dosing reference

CJC-1295 (no DAC) + Ipamorelin Blend dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyNone established
Full research pageCycle-length evidenceComparePrefer Amiravo on Google
Regulatory status
Not approved — research use only
Human amounts
None established in humans
Route studied
—
Frequency
Not established
Half-life
Not established
Evidence grade
Not yet assessed
Vial sizes on the market
4 mg · 10 mg · 20 mg
Other forms seen
—

What CJC-1295 (no DAC) + Ipamorelin Blend is

This blend combines modified GRF 1-29 (CJC-1295 without DAC) with ipamorelin, two peptides studied together in research on growth hormone secretion.

No mechanistic study of the two peptides administered together was identified, so no combined mechanism is described here 10. The components are summarised separately below, and each has its own page. Components CJC-1295 (no DAC) ( /library/cjc-1295-no-dac ): the published CJC-1295 pharmacology concerns albumin-binding GRF(1-29) bioconjugates whose extended duration depends on the drug affinity complex this… How it works →

Key evidence

  • Andersen et al., Growth Horm IGF Res · 2001 · Rats (8-month-old females, methylprednisolone-induced catabolism)
    Maximum tetanic tension and periosteal bone formation rate were higher with ipamorelin plus glucocorticoid than with glucocorticoid alone; ipamorelin was given without any GHRH analog, so this is not a study of the blend. 5
  • Mayfield et al., Am J Sports Med · 2026 · Literature (injectable peptides)
    States that CJC-1295 combined with ipamorelin significantly improved maximum tetanic tension in murine models of glucocorticoid-induced muscle loss; the primary rat literature measuring that endpoint used ipamorelin alone. 4
  • Teichman et al., J Clin Endocrinol Metab · 2006 · Humans (healthy adults)
    The DAC form of CJC-1295 was associated with dose-dependent increases in growth hormone and IGF-1 and a multi-day estimated half-life; the no-DAC component on this page was not studied. 1
All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered CJC-1295 (no DAC) + Ipamorelin Blend. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for CJC-1295 (no DAC) + Ipamorelin Blend.

Cycle-length evidence for CJC-1295 (no DAC) + Ipamorelin Blend

CJC-1295 (no DAC) + Ipamorelin Blend draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength
sizes on the market
2 · Water added
3 · Amount per draw
4 · Syringe
Your mix
10 mg + 2 mL water = 5 mg/mL
10 units holds 0.5 mg (500 mcg)
Draw toEnter an amount in step 3
0102030405060708090100
U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Watermg/mLDraw
0.5 mL20—
1 mL10—
1.5 mL6.667—
2 mL5—
2.5 mL4—
3 mL3.333—
5 mL2—

Supplies and handling

  • Lyophilized vial
    Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
  • Sterile diluent
    The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
  • Graduated syringes
    Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
  • Alcohol prep pads
    For wiping vial stoppers before each puncture.
  • Nitrile gloves
    Clean gloves for aseptic handling.
  • Sharps container
    Puncture-resistant container for used needles.
Step-by-step reconstitution guideStorage and transport accessories

Storage

General research-context handling only, and there is an added consideration for a multi-component vial: the two components are separate molecules with separate stability and solubility behaviour, and no published stability data for them combined in one container were identified. Defer to the supplier's own stability and handling documentation for the specific lot. No preparation or administration instructions are given on this page.

  • Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
  • Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
  • Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent
The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed
Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles
Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution
This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed
Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status
Neither component is FDA-approved for any indication and no approved combination product exists 7,8. Ipamorelin reached company-sponsored clinical development for postoperative ileus and was not approved 3. Neither CJC-1295 nor ipamorelin appears on FDA's May 14, 2026 list of bulk drug substances nominated for compounding under section 503A, in any category 9.
United States (FDA)
No FDA-approved application exists for either component or for the combination 7,12. Ipamorelin was taken into registered clinical trials for postoperative gastrointestinal recovery and was not approved 3. Neither substance appears in category 1, 2 or 3 of FDA's May 14, 2026 503A bulk drug substances list 9. A 2026 analysis of Pharmacy Compounding Advisory Committee recommendations discusses the compounded peptide category these products are marketed within 8.
Sport (WADA)
Section S2.2.4 of the WADA 2026 Prohibited List names CJC-1295 among GHRH analogues and ipamorelin among growth hormone secretagogues and mimetics, with examples introduced by "including, but not limited to"; the class is prohibited at all times 11. The list names CJC-1295 without distinguishing the DAC and no-DAC forms 11. A published plasma assay detects both ipamorelin and CJC-1295 at sub-nanogram concentrations 14.

Status varies by country and changes over time. How we describe regulatory status.

CJC-1295 (no DAC) + Ipamorelin Blend compared with related compounds

CompoundStatusEvidenceHuman amountsHalf-life
CJC-1295 (no DAC) + Ipamorelin BlendNot approved — research use only—None established—
CJC-1295 (no DAC)Not approved — research use onlyCNone establishedNo half-life data specific to the no-DAC
IpamorelinNot approved — research use onlyBNone establishedTerminal half-life of about 2 hours in h
GHRP-6Not approved — research use onlyBNone established—
BPC-157 + TB-500 BlendNot approved — research use onlyCNone established—
CJC-1295 (no DAC) + GHRP-6 BlendNot approved — research use only—None established—

Frequently asked questions

What doses of CJC-1295 (no DAC) + Ipamorelin Blend have been studied in humans?
None that establish an amount. CJC-1295 (no DAC) + Ipamorelin Blend is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.
Is there an established CJC-1295 (no DAC) + Ipamorelin Blend cycle length?
No. We found no human studies that report treatment duration for CJC-1295 (no DAC) + Ipamorelin Blend.
How much bacteriostatic water should be added to a CJC-1295 (no DAC) + Ipamorelin Blend vial?
There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.
How many units is a given amount on an insulin syringe?
On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.
Is CJC-1295 (no DAC) + Ipamorelin Blend FDA-approved?
Not approved — research use only. Neither component is FDA-approved for any indication and no approved combination product exists 7,8. Ipamorelin reached company-sponsored clinical development for postoperative ileus and was not approved 3. Neither CJC-1295 nor ipamorelin appears on FDA's May 14, 2026 list of bulk drug substances nominated for compounding under section 503A, in any category 9.

References

  1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology. 2005
  2. Ipamorelin, the first selective growth hormone secretagogue Eur J Endocrinol. 1998
  3. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus J Pharmacol Exp Ther. 2009
  4. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians Am J Sports Med. 2026
  5. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats Growth Horm IGF Res. 2001
  6. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats Growth Horm IGF Res. 2009
  7. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Front Endocrinol (Lausanne). 2026
  8. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Int J Pharm Compd. 2026
  9. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  10. PubMed search: "CJC-1295" AND ipamorelin (11 records, none an experiment on the combination; searched 22 October 2026) PubMed. 2026
  11. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
  12. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications JBJS Rev. 2026
  13. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs Mo Med. 2026
  14. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry Anal Bioanal Chem. 2013

Last reviewed October 22, 2026 by the Amiravo editorial team. Editorial policy · Report an error